Ciencias de la Salud
Campo de conocimiento
![Foto de Ciencias de la Salud](/img/noimage.png)
![Foto de Ninewells Hospital](/img/noimage_org.png)
Ninewells Hospital
Dundee, Reino UnidoPublicaciones en colaboración con investigadoras/es de Ninewells Hospital (15)
2024
-
Predictors of anastomotic leak and conduit necrosis after oesophagectomy: Results from the oesophago-gastric anastomosis audit (OGAA)
European Journal of Surgical Oncology, Vol. 50, Núm. 6
2023
2022
-
Textbook outcome following oesophagectomy for cancer: international cohort study
British Journal of Surgery, Vol. 109, Núm. 5, pp. 439-449
-
Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery
BJS Open, Vol. 6, Núm. 1
2021
-
Global wealth disparities drive adherence to COVID-safe pathways in head and neck cancer surgery
BJS Open
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
-
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score
British Journal of Surgery, Vol. 19, Núm. 4
-
Mapping the human genetic architecture of COVID-19
Nature, Vol. 600, Núm. 7889, pp. 472-477
-
Mortality from esophagectomy for esophageal cancer across low, middle, and high-income countries: An international cohort study
European Journal of Surgical Oncology, Vol. 47, Núm. 6, pp. 1481-1488
-
Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: An international cohort study
BMJ Open, Vol. 11, Núm. 11
-
Postoperative outcomes in oesophagectomy with trainee involvement
BJS Open, Vol. 5, Núm. 6
2013
-
Lessons from the Hvidoere International Study Group on childhood diabetes: Be dogmatic about outcome and flexible in approach
Pediatric Diabetes, Vol. 14, Núm. 7, pp. 473-480
2012
-
Mortality after surgery in Europe: A 7 day cohort study
The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065
2009
-
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228